MAD Study of IA-14069 for Rheumatoid Arthritis
This study is testing a new oral medicine called IA-14069. Researchers want to learn about its safety, how much of it stays in your body (pharmacokinetics), and what effects it has (pharmacodynamics). The study includes healthy volunteers and people with rheumatoid arthritis (RA) who are already taking methotrexate. Some participants will receive IA-14069, others will receive a placebo (an inactive substance), and some will receive methotrexate. The main goal is to track any side effects and how severe they are. The study plans to enroll 75 people. The current recruitment status is unclear.
- Study design
- This study is testing different doses of IA-14069 in healthy individuals and those with rheumatoid arthritis. It plans to include 75 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main safety information will be collected for up to 35 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
MAD Study of IA-14069
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Incidnece and severity of adverse eventsup to Day 35
Incidence and severity of adverse events (AEs) and serious AEs, including clinical laboratory values, vital signs, 12-lead electrocardiograms, and physical examination; changes from baseline.